DDInter575 DDInter927
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Disopyramide {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Disopyramide {u} (Compound) resembles {v} (Compound) Isopropamide
Disopyramide {u} (Compound) binds {v} (Gene) CHRM2
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
Disopyramide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Disopyramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Abarelix
Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Disopyramide (Compound) resembles Isopropamide (Compound)
Disopyramide (Compound) binds CHRM2 (Gene)
Disopyramide (Compound) upregulates KIAA0355 (Gene)
Disopyramide (Compound) causes Cardiac arrest (Side Effect)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human
Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Disopyramide may lead to a major life threatening interaction when taken with Abarelix